BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
BioVie提供的数据显示，Bezisterim有可能以与阿尔茨海默氏病和生物标志物终点相关的方式减轻炎症和恢复动态平衡
"Bezisterim" has been approved as the non-proprietary name for NE3107
Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation
“Bezisterim” 已被批准为 NE3107 的非专有名称
数据显示 bezisterim 如何通过与痴呆、新陈代谢和炎症相关的特定基因恢复动态平衡
CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston, Massachusetts April 23-25.
内华达州卡森城，2024年4月25日（GLOBE NEWSWIRE）——BioVie Inc.（纳斯达克股票代码：BIVI）（“BioVie” 或 “公司”）是一家临床阶段的公司，正在开发治疗包括神经系统和神经退行性疾病以及肝病在内的慢性衰弱性疾病的创新药物疗法。该公司今天宣布，一份口头陈述和海报揭示了有关贝齐斯特里姆可能如何恢复的更多数据动态平衡是在4月23日至25日在马萨诸塞州波士顿举行的第十二届阿尔茨海默氏症和帕金森氏症药物研发年度峰会上发表的。
The presentation...
演示...
登录免费看全文
登录/注册